Advertisement

Conventional Treatment of Chronic Hypoparathyroidism

  • Lars RejnmarkEmail author
Chapter

Abstract

Long-term supplementation with an active vitamin D analogue and oral calcium supplementation is the mainstay of the treatment of hypoparathyroidism. Doses have to be titrated against the serum calcium concentration while avoiding hypercalciuria. Thiazide diuretics may be used to lower urinary calcium, and magnesium supplementations may be prescribed to patients with hypomagnesemia. Fluctuations in serum calcium levels sometimes occur unpredictably without prior changes in the dose of calcium supplements or vitamin D analogues. Patients should be educated to be aware of symptoms of hypo- or hypercalcemia. Serum levels of calcium, phosphorous, and magnesium as well as renal function should be monitored with 3-month intervals. Most of our knowledge on the treatment of hypoparathyroidism is based on experiences from small case series. There is a need for further studies in order to provide evidence-based approaches to the treatment of hypoparathyroidism and how to avoid complications to the disease.

Keywords

Calcitriol Alfacalcidol Calciferol Vitamin D Calcium supplement Conventional treatment Thiazide diuretics Magnesium Phosphorous Amiloride Hypocalcemia Hypercalcemia Conventional treatment Hypocalcemia Vitamin D intoxication 

References

  1. 1.
    Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L, the hypoparathyroid study group (2011) The effect of adding PTH (1–84) to conventional treatment of hypoparathyroidism – A randomized, placebo controlled study. J Bone Miner Res 26:2358–2370Google Scholar
  2. 2.
    Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277–2285CrossRefPubMedGoogle Scholar
  3. 3.
    Bagó AG, Dimitrov E, Saunders R, Seress L, Palkovits M, Usdin TB, Dobolyi A (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128–147CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Hadker N, Egan J, Sanders J, Lagast H, Clarke B (2014) Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract 20(7):671–679CrossRefPubMedGoogle Scholar
  5. 5.
    Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215–222CrossRefPubMedGoogle Scholar
  6. 6.
    Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J, Bilezikian JP (2013) The effect of PTH(1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356–2361CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Mortensen L, Hyldstrup L, Charles P (1997) Effect of vitamin D treatment in hypoparathyroid patients: a study on calcium, phosphate and magnesium homeostasis. Eur J Endocrinol 136:52–60CrossRefPubMedGoogle Scholar
  8. 8.
    Rude RK, Oldham SB, Singer FR (1976) Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf) 5:209–224CrossRefGoogle Scholar
  9. 9.
    Liebman SE, Taylor JG, Bushinsky DA (2006) Idiopathic hypercalciuria. Curr Rheumatol Rep 8:70–75CrossRefPubMedGoogle Scholar
  10. 10.
    Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730–735PubMedGoogle Scholar
  11. 11.
    Heaney RP, Smith KT, Recker RR, Hinders SM (1989) Meal effects on calcium absorption. Am J Clin Nutr 49:372–376PubMedGoogle Scholar
  12. 12.
    Mortensen L, Charles P (1996) Bioavailability of calcium supplements and the effect of Vitamin D: comparisons between milk, calcium carbonate, and calcium carbonate plus vitamin D. Am J Clin Nutr 63:354–357PubMedGoogle Scholar
  13. 13.
    Reid IR, Bolland MJ, Grey A (2010) Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) 73:689–695CrossRefGoogle Scholar
  14. 14.
    Heaney RP, Kopecky S, Maki KC, Hathcock J, MacKay D, Wallace TC (2012) A review of calcium supplements and cardiovascular disease risk. Adv Nutr 3:763–771CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Lembo A, Camilleri M (2003) Chronic constipation. N Engl J Med 349:1360–1368CrossRefPubMedGoogle Scholar
  16. 16.
    Singh N, Singh PN, Hershman JM (2000) Effect of calcium carbonate on the absorption of levothyroxine. JAMA 283:2822–2825CrossRefPubMedGoogle Scholar
  17. 17.
    Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT (1992) Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 36:830–832CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Davies M, Taylor CM, Hill LF, Stanbury SW (1977) 1,25-dihydroxycholecalciferol in hypoparathyroidism. Lancet 309:55–59CrossRefGoogle Scholar
  19. 19.
    Lund B, Sorensen OH, Lund B, Bishop JE, Norman AW (1980) Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab 51:606–610CrossRefPubMedGoogle Scholar
  20. 20.
    Brumbaugh PF, Haussler DH, Bressler R, Haussler MR (1974) Radioreceptor assay for 1,25-dihydroxyvitamin D3. Science 183:1089–1091CrossRefPubMedGoogle Scholar
  21. 21.
    Avioli LV (1974) The therapeutic approach to hypoparathyroidism. Am J Med 57:34–42CrossRefPubMedGoogle Scholar
  22. 22.
    Russell RGG, Walton RJ, Smith R, Preston C, Basson R, Henderson RG, Norman AW (1974) 1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism. Lancet 304:14–17CrossRefGoogle Scholar
  23. 23.
    Hill LF, Davies M, Taylor CM, Standbury SW (1976) Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clin Endocrinol (Oxf) 5(Suppl):167S–173SCrossRefGoogle Scholar
  24. 24.
    Jorgensen H, Vogt JH (1977) 1alpha-hydroxycholecalciferol in the treatment of hypoparathyroidism. Acta Med Scand 201:3–7CrossRefPubMedGoogle Scholar
  25. 25.
    Neer RM, Holick MF, DeLuca HF, Potts J (1975) Effects of 1a-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 on calcium and phosphorus metabolism in hypoparathyroidism. Metabolism 24:1403–1413CrossRefPubMedGoogle Scholar
  26. 26.
    Kanis JA, Russell RGG, Smith R (1977) Physiological and therapeutic differences between vitamin D, its metabolites and analogues. Clin Endocrinol (Oxf) 7:191s–201sCrossRefGoogle Scholar
  27. 27.
    Haussler MR, Cordy PE (1982) Metabolites and analogues of vitamin d: which for what? JAMA 247:841–844CrossRefPubMedGoogle Scholar
  28. 28.
    Quack I, Zwernemann C, Weiner SM, Sellin L, Henning BF, Waldherr R, Büchner NJ, Stegbauer J, Vonend O, Rump LC (2005) Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review. Exp Clin Endocrinol Diabetes 113:376–380CrossRefPubMedGoogle Scholar
  29. 29.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281CrossRefPubMedGoogle Scholar
  30. 30.
    Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507–4514CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Massey LK, Whiting SJ (1996) Dietary salt, urinary calcium, and bone loss. J Bone Miner Res 11:731–736CrossRefPubMedGoogle Scholar
  32. 32.
    Rizzoli R, Hugi K, Fleisch H, Bonjour JP (1981) Effect of hydrochlorothiazide on 1,25-dihydroxyvitamin D3-induced changes in calcium metabolism in experimental hypoparathyroidism in rats. Clin Sci (Lond) 60:101–107Google Scholar
  33. 33.
    Santos F, Smith MJV, Chan JCM (1986) Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3) action of hydrochlorothiazide. Am J Dis Child 140:139–142CrossRefPubMedGoogle Scholar
  34. 34.
    Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ, Suki WN (1978) Treatment of hypoparathyroid patients with chlorthalidone. N Engl J Med 298:577–581CrossRefPubMedGoogle Scholar
  35. 35.
    Xu H, Zisman AL, Coe FL, Worcester EM (2013) Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother 14:435–447CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L (2003) Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 33:41–50CrossRefPubMedGoogle Scholar
  37. 37.
    Wang S, McDonnell EH, Sedor FA, Toffaletti JG (2002) pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med 126:947–950PubMedGoogle Scholar
  38. 38.
    Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2001) Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med 250:144–153CrossRefPubMedGoogle Scholar
  39. 39.
    Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163–170CrossRefPubMedGoogle Scholar
  40. 40.
    Tambyah PA, Ong BK, Lee KO (1993) Reversible parkinsonism and asymptomatic hypocalcemia with basal ganglia calcification from hypoparathyroidism 26 years after thyroid surgery. Am J Med 94:444–445CrossRefPubMedGoogle Scholar
  41. 41.
    Pohjola S (1962) Ocular manifestations of idiopathic hypoparathyroidism. Acta Ophthalmol 40:255–265CrossRefGoogle Scholar
  42. 42.
    Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S (2012) Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 77:200–206CrossRefGoogle Scholar
  43. 43.
    Malberti F (2013) Hyperphosphataemia: treatment options. Drugs 73:673–688CrossRefPubMedGoogle Scholar
  44. 44.
    Levi J, Massry SG, Coburn JW, Llach F, Kleeman CR (1974) Hypocalcemia in magnesium-depleted dogs: evidence for reduced responsiveness to parathyroid hormone and relative failure of parathyroid gland function. Metabolism 23:323–335CrossRefPubMedGoogle Scholar
  45. 45.
    Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP (1984) The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 310:1221–1225CrossRefPubMedGoogle Scholar
  46. 46.
    Rösler A, Rabinowitz D (1973) Magnesium-induced reversal of vitamin-D resistance in hypoparathyroidism. Lancet 301:803–805CrossRefGoogle Scholar
  47. 47.
    Jones KH, Fourman P (1966) Effects of infusions of magnesium and of calcium in parathyroid insufficiency. Clin Sci 30:139–150PubMedGoogle Scholar
  48. 48.
    Dent CE, Harper CM, Morgans M, Philpot GR, Trotter WR (1955) Insensitivity of vitamin D developing during the treatment of postoperative tetany; its specificity as regards the form of vitamin D taken. Lancet 266:687–690CrossRefGoogle Scholar
  49. 49.
    Elin RJ, Hosseini JM, Fitzpatrick L, Bliziotes MM, Marx SJ (1990) Blood magnesium status of patients with parathyroid disease. Magnes Trace Elem 9:119–123PubMedGoogle Scholar
  50. 50.
    Quamme GA, Carney SL, Wong NL, Dirks JH (1980) Effect of parathyroid hormone on renal calcium and magnesium reabsorption in magnesium deficient rats. Pflugers Arch 386:59–65CrossRefPubMedGoogle Scholar
  51. 51.
    Quamme GA (1997) Renal magnesium handling: new insights in understanding old problems. Kidney Int 52:1180–1195CrossRefPubMedGoogle Scholar
  52. 52.
    Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R (2010) A case series of proton pump inhibitor – induced hypomagnesemia. Am J Kidney Dis 56:112–116CrossRefPubMedGoogle Scholar
  53. 53.
    Lubi M, Tammiksaar K, Matjus S, Vasar E, Volke V (2012) Magnesium supplementation does not affect blood calcium level in treated hypoparathyroid patients. J Clin Endocrinol Metab 97:E2090–E2092CrossRefPubMedGoogle Scholar
  54. 54.
    Ryan MP (1986) Magnesium and potassium-sparing diuretics. Magnesium 5:282–292PubMedGoogle Scholar
  55. 55.
    Murdoch DL, Forrest G, Davies DL, McInnes GT (1993) A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. Br J Clin Pharmacol 35:373–378CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    McIlroy J, Dryburgh F, Hinnie J, Dargie R, Al-Rawi A (1999) Oestrogen and calcium homeostasis in women with hypoparathyroidism. BMJ 319:1252–1253CrossRefPubMedCentralPubMedGoogle Scholar
  57. 57.
    Hepburn NC, Abdul-Aziz LA, Whiteoak R (1989) Danazol-induced hypercalcaemia in alphacalcidol-treated hypoparathyroidism. Postgrad Med J 65:849–850CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Verbeelen D, Fuss M (1979) Hypercalcaemia induced by oestrogen withdrawal in vitamin D-treated hypoparathyroidism. BMJ 1:522–523CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    de Nagant DC (1979) Oestrogen-induced hypocalcaemia in hypoparathyroidism. BMJ 1:1563–1564CrossRefGoogle Scholar
  60. 60.
    Mallette LE (1992) Case report: hypoparathyroidism with menses-associated hypocalcemia. Am J Med Sci 304:32–37CrossRefPubMedGoogle Scholar
  61. 61.
    Moller UK, Streym S, Jensen LT, Mosekilde L, Schoenmakers I, Nigdikar S, Rejnmark L (2013) Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients 5:3470–3480CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Cundy T, Haining SA, Guilland-Cumming DF, Butler J, Kanis JA (1987) Remission of hypoparathyroidism during lactation: evidence for a physiological role for prolactin in the regulation of vitamin D metabolism. Clin Endocrinol (Oxf) 26:667–674CrossRefGoogle Scholar
  63. 63.
    Rude RK, Haussler MR, Singer FR (1984) Postpartum resolution of hypocalcemia in a lactating hypoparathyroid patient. Endocrinol Jpn 31:227–233CrossRefPubMedGoogle Scholar
  64. 64.
    Wright AD, Joplin GF, Dixon HG (1969) Post-partum hypercalcaemia in treated hypoparathyroidism. BMJ 1:23–25CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Lepre F, Grill V, Ho PWM, Martin TJ (1993) Hypercalcemia in pregnancy and lactation associated with parathyroid hormone-related protein. N Engl J Med 328:666–667CrossRefPubMedGoogle Scholar
  66. 66.
    Sato K (2008) Hypercalcemia during pregnancy, puerperium, and lactation: review and a case report of hypercalcemic crisis after delivery Due to excessive production of PTH-related protein (PTHrP) without malignancy (humoral hypercalcemia of pregnancy). Endocr J 55:959–966CrossRefPubMedGoogle Scholar
  67. 67.
    LeGrand SB, Leskuski D, Zama I (2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 149:259–263CrossRefPubMedGoogle Scholar
  68. 68.
    Wisneski LA (1990) Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46(Suppl):S26–S30CrossRefPubMedGoogle Scholar
  69. 69.
    Spaulding WB, Yendt ER (1964) Prolonged vitamin D intoxication in a patient with hypoparathyroidism. Can Med Assoc J 90:1049–1054PubMedCentralPubMedGoogle Scholar
  70. 70.
    Hossain M (1970) Vitamin-D intoxication during treatment of hypoparathyroidism. Lancet 295:1149–1151CrossRefGoogle Scholar
  71. 71.
    Stamp TCB (1981) Calcitriol dosage in osteomalacia, hypoparathyroidism and attempted treatment of myositis ossificans progressiva. Curr Med Res Opin 7:316–336CrossRefPubMedGoogle Scholar
  72. 72.
    Ireland AW, Clubb JS, Neale FC, Posen S, Reeve TS (1968) The calciferol requirements of patients with surgical hypoparathyroidism. Ann Intern Med 69:81–89CrossRefPubMedGoogle Scholar
  73. 73.
    Kitamura N, Shigeno C, Shiomi K, Lee K, Ohta S, Sone T, Katsushima S, Tadamura E, Kousaka T, Yamamoto I (1990) Episodic fluctuation in serum intact parathyroid hormone concentration in men. J Clin Endocrinol Metab 70:252–263CrossRefPubMedGoogle Scholar
  74. 74.
    Shrestha RP, Hollot CV, Chipkin SR, Schmitt CP, Chait Y (2010) A mathematical model of parathyroid hormone response to acute changes in plasma ionized calcium concentration in humans. Math Biosci 226:46–57CrossRefPubMedGoogle Scholar
  75. 75.
    Promberger R, Ott J, Kober F, Karik M, Freissmuth M, Hermann M (2011) Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomy. Thyroid 21:145–150CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.Department of Endocrinology and Internal MedicineAarhus University HospitalAarhus CDenmark

Personalised recommendations